<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002711</url>
  </required_header>
  <id_info>
    <org_study_id>95-073</org_study_id>
    <secondary_id>CDR0000064528</secondary_id>
    <secondary_id>NCI-H95-0791</secondary_id>
    <nct_id>NCT00002711</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus</brief_title>
  <official_title>A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining radiation therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy and radiation&#xD;
      therapy in treating patients with cancer of the esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Estimate the maximum tolerated dose and recommend a phase II dose for&#xD;
      paclitaxel (TAX) when administered as a 96-hour intravenous infusion with a weekly fixed dose&#xD;
      of intravenous cisplatin (CDDP) during concurrent radiotherapy for patients with localized&#xD;
      esophageal cancer. II. Estimate the response rate of patients treated with 2 courses of&#xD;
      TAX/CDDP induction chemotherapy and the complete response rate of patients treated with&#xD;
      TAX/CDDP and concurrent radiotherapy. III. Describe the toxic effects of TAX/CDDP prior to&#xD;
      and during radiotherapy. IV. Describe the pharmacokinetics of TAX as a continuous infusion&#xD;
      (CI) over 96 hours. V. Evaluate, by flow cytometry, the ability of CI TAX to block esophageal&#xD;
      cancer cells in the G2-M phase of the cell cycle.&#xD;
&#xD;
      OUTLINE: After the MTD of TAX is reached on Part A, new patients are entered on Part B. The&#xD;
      following acronyms are used: CDDP Cisplatin, NSC-119875 EBRT External-beam radiotherapy TAX&#xD;
      Paclitaxel (Bristol-Myers), NSC-125973 PART A: Radiotherapy plus 2-Drug Combination&#xD;
      Chemotherapy. EBRT using megavoltage equipment (&gt;/= 10 MV recommended; electron boost allowed&#xD;
      for subclavicular fossae); plus TAX/CDDP. PART B: 2-Drug Combination Induction Chemotherapy&#xD;
      followed by Radiotherapy plus 2-Drug Combination Chemotherapy. TAX/CDDP; followed by EBRT as&#xD;
      in Part A; plus TAX/CDDP.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 3 patients/dose will be entered on Part A (up to 24 patients) and&#xD;
      3-6 patients on Part B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1995</start_date>
  <completion_date type="Actual">October 2000</completion_date>
  <primary_completion_date type="Actual">October 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET electron therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>low-LET photon therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed epidermoid carcinoma or adenocarcinoma of&#xD;
        the esophagus eligible for potentially curative radiotherapy Disease in one of the&#xD;
        following categories: Newly diagnosed Locoregional failure after prior resection with&#xD;
        curative intent Positive microscopic margin after palliative resection of all gross disease&#xD;
        Disease clinically limited to esophagus T 1-4, any N, M0 Gastroesophageal junction tumor&#xD;
        allowed No positive pleural, pericardial, or peritoneal cytology No tracheobronchial&#xD;
        invasion on bronchoscopy, including tracheoesophageal fistula&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100%&#xD;
        Hematopoietic: WBC more than 4,000/mm3 Platelet count at least 150,000/mm3 Hepatic:&#xD;
        Bilirubin no greater than 1.5 mg/dL Renal: Creatinine no greater than 1.5 mg/dL OR&#xD;
        Creatinine clearance at least 65 mL/min per 1.73 square meters Cardiovascular: No NYHA&#xD;
        class 3/4 status No cerebral vascular disease No hypertension Other: No severe uncontrolled&#xD;
        diabetes No uncontrolled infection No other medical condition that precludes treatment No&#xD;
        mental status abnormality that precludes comprehension of or compliance with treatment No&#xD;
        active cancer arising at another primary site other than basal cell carcinoma of the skin&#xD;
        or in situ cervical carcinoma&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Paul Kelsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2004</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

